Recent study results from the Annals of Oncology suggest that the Galleri blood test, an assay (a laboratory procedure for assessing or measuring the presence, amount, or activity of a target entity) that can detect up to 50 types of cancers, may become a useful oncology screening procedure.
The Galleri blood test may establish a new method for screening individuals for multiple cancers with a single blood test.
The blood test uses next-generation sequencing (a genetic testing procedure) to analyze the arrangement of circulating cell-free DNA (DNA levels are elevated in cancer) from a blood sample. The Galleri blood test has a cancer specificity detection rate of 99.5% but the overall sensitivity of the test for any stage of cancer was only 51.5%. The Galleri blood test may establish a new method for screening individuals for multiple cancers with a single blood test, in contrast to the traditional clinical scenario wherein only individual cancers are screened. Currently, the test has not been approved by the U.S. Food and Drug Administration and will cost $950.
About Women’s Cancer Research Foundation The Women’s Cancer Research Foundation (WCRF) is one of Southern California’s and the nation’s most active research organizations for female cancers. We are dedicated to serving the interests of patients, families, and friends affected by women’s cancers. WCRF partners with physician-scientists nationally to make differences in women’s lives by offering hope, strength, and progress.
361 Hospital Road, Suite 422
Newport Beach, CA 92663
PH: (949) 642-5165